Literature DB >> 22939854

Prevention of the second stage of epithelial loss is a potential novel treatment for bronchiolitis obliterans.

Yunge Zhao1, John F Steidle1, Gilbert R Upchurch1, Irving L Kron1, Christine L Lau2.   

Abstract

OBJECTIVES: Loss of epithelial cells is one of the key factors that lead to airway fibrosis. Loss of epithelial cells may decrease the barrier to host cell infiltration into the lumen, allowing deposition of extracellular matrix, with subsequent obliteration of the airway. The objective of this study was to determine whether injection of epithelial cells/progenitor cells from the recipient into the lumen of the donor trachea could prevent bronchiolitis obliterans (BO) in a mouse heterotopic tracheal transplantation (HTT) model.
METHODS: A major histocompatibility complex class I and class II mismatch of mouse HTT model of BO was used. Epithelial cells from recipient mice were isolated and reinjected into the lumen of the allografts on day 3 after transplantation. Rag-1 knock-out and isografts were also performed as controls. The grafts were analyzed by immunohistochemistry and densitometric analysis.
RESULTS: The results demonstrated that tracheal epithelium was lost by day 3, regenerated between 3 to 7 days, and was lost again in all allografts, but not in the isografts or in Rag-1 knock-out groups by day 12. The reconstituted epithelium was donor originated on day 7 based on green fluorescent protein staining. Furthermore, with the injection of recipient cells into the tracheal lumen, loss of the epithelium was not observed and the luminal obliteration was significantly less in the allografts.
CONCLUSIONS: Injection of recipient epithelial cells prevents the second phase of epithelial loss and significantly decreases BO development in an HTT model. Clinically, the use of injected recipient epithelial cells could be a novel treatment for BO. Published by Mosby, Inc.

Entities:  

Mesh:

Year:  2012        PMID: 22939854      PMCID: PMC3602313          DOI: 10.1016/j.jtcvs.2012.07.098

Source DB:  PubMed          Journal:  J Thorac Cardiovasc Surg        ISSN: 0022-5223            Impact factor:   5.209


  25 in total

Review 1.  Bronchiolitis obliterans: an update.

Authors:  Andrew Chan; Roblee Allen
Journal:  Curr Opin Pulm Med       Date:  2004-03       Impact factor: 3.155

2.  The role of respiratory epithelium in a rat model of obliterative airway disease.

Authors:  B F Adams; T Brazelton; G J Berry; R E Morris
Journal:  Transplantation       Date:  2000-02-27       Impact factor: 4.939

3.  Basal cells are the progenitors of primary tracheal epithelial cell cultures.

Authors:  J R Ford; M Terzaghi-Howe
Journal:  Exp Cell Res       Date:  1992-01       Impact factor: 3.905

4.  In vitro and in vivo growth and differentiation of clones of tracheal basal cells.

Authors:  Y Inayama; G E Hook; A R Brody; A M Jetten; T Gray; J Mahler; P Nettesheim
Journal:  Am J Pathol       Date:  1989-03       Impact factor: 4.307

5.  Increased chimerism of bronchial and alveolar epithelium in human lung allografts undergoing chronic injury.

Authors:  Wolfram Kleeberger; Anne Versmold; Thomas Rothämel; Sabine Glöckner; Martin Bredt; Axel Haverich; Ulrich Lehmann; Hans Kreipe
Journal:  Am J Pathol       Date:  2003-05       Impact factor: 4.307

6.  Depletion of tissue plasminogen activator attenuates lung ischemia-reperfusion injury via inhibition of neutrophil extravasation.

Authors:  Yunge Zhao; Ashish K Sharma; Damien J LaPar; Irving L Kron; Gorav Ailawadi; Yuan Liu; David R Jones; Victor E Laubach; Christine L Lau
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2011-03-04       Impact factor: 5.464

7.  Orthotopic tracheal transplantation in the murine model.

Authors:  Eric M Genden; Peter Boros; Jianhua Liu; Jonathan S Bromberg; Lloyd Mayer
Journal:  Transplantation       Date:  2002-05-15       Impact factor: 4.939

8.  RAG-1-deficient mice have no mature B and T lymphocytes.

Authors:  P Mombaerts; J Iacomini; R S Johnson; K Herrup; S Tonegawa; V E Papaioannou
Journal:  Cell       Date:  1992-03-06       Impact factor: 41.582

Review 9.  The heterotopic tracheal allograft as an animal model of obliterative bronchiolitis.

Authors:  D J Hele; M H Yacoub; M G Belvisi
Journal:  Respir Res       Date:  2001-04-05

Review 10.  Human airway xenograft models of epithelial cell regeneration.

Authors:  E Puchelle; B Peault
Journal:  Respir Res       Date:  2000-10-12
View more
  4 in total

1.  Rapamycin prevents bronchiolitis obliterans through increasing infiltration of regulatory B cells in a murine tracheal transplantation model.

Authors:  Yunge Zhao; Jacob R Gillen; Akshaya K Meher; Jordan A Burns; Irving L Kron; Christine L Lau
Journal:  J Thorac Cardiovasc Surg       Date:  2015-09-07       Impact factor: 5.209

2.  Short-course rapamycin treatment preserves airway epithelium and protects against bronchiolitis obliterans.

Authors:  Jacob R Gillen; Yunge Zhao; David A Harris; Damien J LaPar; Irving L Kron; Christine L Lau
Journal:  Ann Thorac Surg       Date:  2013-06-24       Impact factor: 4.330

3.  Treatment with placenta-derived mesenchymal stem cells mitigates development of bronchiolitis obliterans in a murine model.

Authors:  Yunge Zhao; Jacob R Gillen; David A Harris; Irving L Kron; Michael P Murphy; Christine L Lau
Journal:  J Thorac Cardiovasc Surg       Date:  2013-11-04       Impact factor: 5.209

4.  Bone marrow-derived multipotent stromal cells attenuate inflammation in obliterative airway disease in mouse tracheal allografts.

Authors:  Alicia Casey; Fabian Dirks; Olin D Liang; Hakima Harrach; Katharina Schuette-Nuetgen; Kristen Leeman; Carla F Kim; Craig Gerard; Meera Subramaniam
Journal:  Stem Cells Int       Date:  2014-09-10       Impact factor: 5.443

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.